Please login to the form below

SGLT2 inhibitor

This page shows the latest SGLT2 inhibitor news and features for those working in and with pharma, biotech and healthcare.

FDA adcomm split on Sanofi’s type 1 diabetes drug

Sanofi and partner Lexicon Pharma have developed the orally-active SGLT1 and SGLT2 inhibitor for this indication on the grounds that it could help type 1 diabetes who struggle to control ... Current SGLT2-selective drugs – such as Johnson &Johnson’s

Latest news

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Boehringer Ingelheim and Lilly’s SGLT2 inhibitor Jardiance (empagliflozin) was the first drug approved by the FDA as being able to reduce the risk of cardiovascular death in patients with type ... products. The LEADER trial of Victoza also showed a 13%
Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Janssen’s type 2 diabetes treatment is in a battle with rival drugs (especialy in its SGLT2 inhibitor class), where proof of cardiovascular benefits are now vital for future market share. ... The first SGLT2 inhibitor to gain this EU label update was
J&J’s Invokana aces diabetic kidney disease trial, setting up filings

Johnson &Johnson’s SGLT2 inhibitor Invokana worked so well in a trial involving diabetics with chronic kidney disease that the study has been halted early – potentially opening up a lucrative new ... risk of lower-limb amputation in diabetics,
J&J says real-world data finds no amputation risk for Invokana

A year ago, regulators slapped warnings to the labelling for Johnson &Johnson’s diabetes drug Invokana, setting it at a disadvantage against rival drugs in the SGLT2 inhibitor class, but now ... results show that the “overall benefit-risk profile of
PMCPA takes AZ to task over asthma drug press release

body. The source of GSK’s anger was a PR put out by AZ after interleukin-5 inhibitor Fasenra (benralizumab) was recommended for approval by the EMA’s Committee for Medicinal ... company in Amsterdam last November relating to SGLT2 inhibitor diabetes

More from news
Approximately 1 fully matching, plus 59 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Medius Deal Watch table for March 2015

Company acquisition. Marketed BTK inhibitor for haematological cancers pipeline incl. 3 products in clinic. ... 165. Brighthaven Ventures/ Islet Sciences. Licence and collaboration. Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes.
Interview: Christopher Boulton, AstraZeneca

Between them, the companies developed the DPP-4 inhibitor Onglyza (saxagliptin), the saxagliptin/metformin combination product Kombiglyze and the SGLT2 inhibitor Forxiga (dapagliflozin), all of which have received approvals in various ... The deal gives
Pharma deals during April 2013

The partnership is to co-develop and commercialise Pfizer's phase III ready oral sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin for the treatment of type 2 diabetes, both as a ... Clearly the pressure is on, the announcement coming only a

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

Pfizer appoints diabetes expert Morris Birnbaum

Pfizer's interests in the area include a collaboration with Merck &Co on the sodium glucose co-transporter (SGLT2) inhibitor ertugliflozin to treat diabetes.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Global Business Development Director – Health Education: excellent commission

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Associate Director: £75, 000-90, 000

Medical Writer: Salary TBC

Senior Medical Writer: Salary TBC

Account Director, Medical Education: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director – Healthcare Marketing – Berks: Salary TBC

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director, Healthcare Marketing Agency: Salary TBC

Account Director – Health Policy – Global Agency: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Manager / Senior Account Manager: 35, 000-40, 000

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...